22.2.2022 09:35:52 CET | Aqua Bio Technology ASA | Non-regulatory press releases

Reference is made to ABT`s stock exchange message 16 February 2022 -
https://newsweb.oslobors.no/message/553926. Nasdaq listed LifeMD -
https://ir.lifemd.com/index.php#/ has now launched 4 products, under the brand
name NavaMD, which are based on ABT's hatching fluid ingredient (Aquabeautine
XL). These products include a Daily Cleanser, Spot Correcting Serum,
Moisturizing Cream, and Revitalizing Eye Cream. See all products under the
"shop" tab at https://social.navamd.com/otc -
https://social.navamd.com/otc?fbclid=IwAR30h8I3qa44hp1T5-1m5h87cPrmsCujDorTvLrzO
YFU_9bOB7KFkDXzOYw

Restorsea has invested +$50M -
https://ir.lifemd.com/LFMD_Investor_Presentation_January_2022.pdf?v=1.0 in
intellectual property & R&D prior to LifeMD's launch of NavaMD. NavaMD is
positioned as an online skincare and telehealth brand that offers
teledermatology services to patients in all 50 states in the US. Teledermatology
represents one of the fastest growing segments of the U.S. telehealth market.
According to Fortune Business Insights -
https://www.globenewswire.com/Tracker?data=28WCLRAkOHJhKPprY20fcmZfQQMP18dGNgsow
VTQDSvXH5kG5ISEnx9NFytgWELlIFVBQczRZCJ8YljKHy0hdSH80HXDa8CpE8PSLvZM-wMR9ojC5isfM
zmtT0augrf3L7WIHmhJcS79hsse4tOTFV_iiU081IaHA7SYSnTrpoB8GWCZKjYQIiyyBc6mLisZAF3gi
bUKvfAGvNJ8Ie5TnOGk30oO0mBCfniosFOBv2HoT8q8F31oFo3ue2kFnbNqNSiNW9-c2hoT1MsWalvxC
zi29TQU6WLsK1Ueiw2EAeFMMmmyhLIeB1EOqLihuE43BzAbBSuj3H-D_q6LQh_Yzk55zcAW07-wtFkZf
C8WIKasrisvv6JaRmon1RRHvFeN, the teledermatology market is expected to grow at a
24.3% CAGR to $44.9 billion by 2027. See further information about Nasdaq listed
LifeMD in their latest corporate presentation released 22 January 2022 -
https://ir.lifemd.com/LFMD_Investor_Presentation_January_2022.pdf?v=1.0.

Restorsea has built its company and business idea around Aquabeautine XL and has
increased its purchase of Aquabeautine XL through 2021 and expanded its
distribution into 2022. Restorsea now has distribution of products, which are
based on ABT's hatching fluid ingredient (Aquabeautine XL), in South Korea, in
the US through Nasdaq listed Hydrafacial, above mentioned Nasdaq listed LifeMD,
approx. 130 stores in the US, and in a number of clinics across Brazil.

***

For further information, please contact CEO Håvard Lindstrøm mobile phone +47
941 32 288.

Aqua Bio Technology is developing and commercializing sustainable biotechnology
for use in skincare products. ABT's cosmetics ingredients are highly effective
and they provide the cosmetics industry with natural alternatives to traditional
ingredients. ABT is also marketing and distributing natural skincare products
developed by partners towards consumers and professional users. ABT's focus on
commercialization and development of natural ingredients and natural skincare
products has been, and will continue to be, an important part of the Company's
strategy going forward. Aqua Bio Technology is listed on the Euronext Expand
market of the Oslo Stock Exchange.

 

CONTACTS

 * Håvard Lindstrøm, 004794132288, hl@aquabiotech.no 

ABOUT AQUA BIO TECHNOLOGY ASA

Aqua Bio Technology (ABT) is developing and commercializing sustainable
biotechnology for use in skin care products. ABT's cosmetics ingredients are
highly effective and they provide the cosmetics industry with natural
alternatives to traditional ingredients. ABT is also marketing and distributing
natural skin care products developed by partners towards consumers and
professional users. Aqua Bio Technology is listed on Euronext Expand.

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17847556/1227/1629/Download%20announcement
%20as%20PDF.pdf